Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00414102
Other study ID # 01-05-TL-375-069
Secondary ID U1111-1115-2043
Status Completed
Phase Phase 4
First received December 19, 2006
Last updated June 27, 2016
Start date October 2006
Est. completion date September 2007

Study information

Verified date May 2010
Source Takeda
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the subjective treatment effects of ramelteon, once daily (QD), on sleep using a post sleep questionnaire-interactive voice response system in adults with chronic insomnia.


Description:

Approximately 60 to 70 million adults in the United States alone are affected by insomnia. Daytime symptoms of insomnia include tiredness, lack of energy, difficulty concentrating, and irritability. Recent epidemiologic research focusing on the quality of life has identified significant insomnia-related conditions that relate to work productivity, health care utilization, and risk of depression. Insomnia is associated with diminished work output, absenteeism, and greater rates of accidents.

Ramelteon is marketed for the treatment of insomnia characterized by difficulty with sleep onset under the brand name of Rozeremâ„¢.

This study will be comprised of two groups of subjects, 1) an outpatient group and 2) an inpatient group. The inpatient group will be used as reference arm as previously conducted studies in the sleep laboratory setting. Study participation is anticipated to be about 50 days (approximately 1.75 months).


Recruitment information / eligibility

Status Completed
Enrollment 552
Est. completion date September 2007
Est. primary completion date September 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria

- Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.

- Body mass index between 18 and 34, inclusive.

- Based on sleep history, has had chronic insomnia for at least 3 months.

- Based on sleep history, reports a history of subjective sleep latency greater than or equal to 60 min and a subjective total sleep time of less than or equal to 6.5 hours.

- The difference of the average subjective sleep latency from days 1-3 to days 5-7 has to be less than or equal to 20 minutes during the single blind run-in period.

- On at least 3 of the first 5 nights of single-blind run-in placebo treatment, the subject must have an subjective sleep latency of greater than or equal to 45 minutes and subjective total sleep time of less than or equal to 6.5 hours.

- Based on sleep history, habitual bedtime is between 10:00 PM and 1:00 AM.

- Willing to have a fixed bedtime and agrees to go to bed within 30 minutes of the habitual bedtime during the entire study.

- Consistent access to a touch-tone phone and are willing to complete all paper and telephone questionnaires within 60 minutes of awakening each morning throughout the entire duration of the study.

- Willing to remain in bed for at least 6.5 hours each night during the entire study.

- Based on sleep history, uses pharmacological assistance to sleep 0 to 4 times per week in the last 3 months.

Exclusion Criteria

- Known hypersensitivity to ramelteon or related compounds, including melatonin, and melatonin related compounds.

- Participated in any other investigational study and/or taken any investigational drug within 30 days or five half-lives prior to the first dose of single-blind study medication, whichever is longer.

- Has sleep schedule changes required by employment (eg, shift worker) within three months prior to the administration of single-blind study medication.

- Has flown across greater than 3 time zones within 7 days prior to screening, or will travel across 2 or more time zones during the course of the study.

- Has participated in a weight loss program or has substantially altered their exercise routine within 30 days prior to the first night of single-blind study medication.

- Has ever had a history of seizures; sleep apnea, restless leg syndrome, periodic leg movement syndrome, chronic obstructive pulmonary disease, fibromyalgia, or a positive test result for the aforementioned ailments on the screening polysomnography.

- History of psychiatric disorder within the past 6 months.

- History of drug addiction or drug abuse within the past 12 months.

- History of alcohol abuse within the past 12 months, as defined in Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Revised, or regularly consumes more than 14 alcoholic drinks per week, or for the inpatient subject consumed any alcoholic drinks within 24 hours of any polysomnography visits.

- Current significant hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematological, neurological, or metabolic disease, unless currently controlled and stable with protocol-allowed medication, within 30 days prior to the first night of single-blind study medication.

- Uses tobacco products or any other products during nightly awakenings that may interfere with the sleep wake cycle.

- Positive urine drug screen at initial screening Visit 2.

- For inpatient subjects: has a positive breathalyzer test on any of the PSG assessment visits.

- Exhibit a placebo response during single blinded placebo run in period.

- Any clinically important abnormal finding as determined by a medical history, physical examination, electrocardiogram, or clinical laboratory tests, as determined by the investigator.

- Any additional condition(s) that in the Investigator's opinion would:

- affect sleep/wake function

- prohibit the subject from completing the study

- indicate that continuation in the study would not be in the best interests of the subject.

- Positive hepatitis panel including hepatitis A virus- Immunoglobulin M, hepatitis-B surface antigen, hepatitis C virus antibody.

- Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including the following:

- Anxiolytics Antipsychotics

- over-the-counter and Prescription Sedatives

- Hypnotics

- Narcotic analgesics

- Antidepressants

- Beta-blockers

- Anticonvulsants

- St. John's wort

- Sedating H1 antihistamines

- Kava-kava

- Systemic steroids

- Ginkgo-biloba

- Respiratory stimulants

- over-the-counter and prescription diet aids

- Sedating Decongestants

- Muscle relaxants

- Melatonin and all other drugs or supplements known to affect sleep/wake function.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Ramelteon
Ramelteon 8mg, tablets, orally, once nightly for up to 28 days.
Placebo
Ramelteon placebo-matching tablets, orally, once nightly for up to 28 days.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Takeda

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Average subjective Sleep Latency from Day 15 to Day 21 Day 22 No
Secondary Subjective Measures of Sleep Latency. Weeks 1 and 2 or Final Visit No
Secondary Subjective Total Sleep Time. Weeks 1, 2 and 3 or Final Visit No
Secondary Wake Time after Sleep Onset Weeks 1, 2 and 3 or Final Visit No
Secondary Number of Awakenings. Weeks 1, 2 and 3 or Final Visit No
Secondary Quality of Sleep. Weeks 1, 2 and 3 or Final Visit No
Secondary Rebound insomnia assessed from Nights 22 to 28 via self-reported sleep latency. Day 29 No
See also
  Status Clinical Trial Phase
Completed NCT03171519 - Effects of Exercise and Acupuncture on Chronic Insomnia N/A
Completed NCT02515006 - Impact of Homeopathy for Persistent Insomnia in Patients With Cancer N/A
Recruiting NCT05247697 - Mirtazapine for Chronic Insomnia in Older Adults Phase 1
Active, not recruiting NCT04366284 - Optimizing the Scalability of Evidence-Based Behavioral Sleep Medicine Practices With a Digital Health Platform N/A
Active, not recruiting NCT04350866 - Enhancing Access to Insomnia Care in VA PCMHI Clinics
Recruiting NCT04761796 - Sleep Time and Insomnia Factors Among Professional Flight Members
Completed NCT02688569 - Sleep and Pain Intervention for Chronic Widespread Pain Pilot Study N/A
Completed NCT02236845 - Pilot Study to Clinical Evaluate Lacrima Medical Device in Insomnia Patients N/A
Completed NCT01949389 - Piloting an Internet-based Therapy for Insomnia in a Population of Veterans With Substance Use Disorders N/A
Completed NCT00671294 - Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia. Phase 3
Completed NCT02392000 - Mobile Sleep Intervention for OEF, OIF and OND Veterans N/A
Recruiting NCT04471168 - Interest of Auriculotherapy in the Management of Chronic Insomnia N/A
Completed NCT02774642 - Integrated CBT-I and PE on Sleep and PTSD Outcomes (Impact Study) N/A
Completed NCT02290405 - Impact of Hyperarousal on Simple and Complex Cognitive Task Performance Among Insomnia Sufferers
Completed NCT05618002 - Lemborexant vs Zopiclone vs Clonidine for Insomnia Treatment in Chronic Pain Patients
Completed NCT01995838 - A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia Phase 2
Recruiting NCT05457790 - Feasibility and Preliminary Efficacy of Acceptance and Commitment Therapy (ACT) for Sleep Disturbances in Adults With Sickle Cell Disease (SCD) N/A
Completed NCT02272712 - The Effectiveness of Online Treatment for Insomnia in Cancer Survivors N/A
Completed NCT00915135 - Efficacy and Safety of Ramelteon on Chronic Insomnia Phase 2
Completed NCT04635098 - DexmedetOmidine Complement Treats Chronic insOmnia and Improves Circadian Rhythm (DOCTOR) N/A